Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 12:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 13,610 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatoses Clear all

Conditions: Breast Cancer, Invasive Breast Cancer, ER-Negative PR-Negative HER2-Negative Breast Cancer
Interventions: Entinostat; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or Non-squamous, Urothelial Carcinoma, Renal Cell Carcinoma, Clear Cell, Castration-resistant Prostate Cancer, Ovarian Cancer, Epithelial, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer
Interventions: XmAb®808, Keytruda® (pembrolizumab); Biological
Lead sponsor: Xencor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 12
States / cities: Los Angeles, California • Denver, Colorado • Sarasota, Florida + 9 more

Conditions: Metastatic Breast Cancer, HER2+ Breast Cancer
Interventions: BKM120, Trastuzumab, Capecitabine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 7
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Tampa, Florida + 4 more

Conditions: HER2-negative Breast Cancer, Metastatic Breast Cancer
Interventions: PLD Chemotherapy, CDX-1140, CDX-301; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 7
States / cities: Chicago, Illinois • Baltimore, Maryland • Chapel Hill, North Carolina + 3 more

Conditions: Mevalonic Aciduria, Mevalonate Kinase Deficiency, Immune System Diseases, Periodic Fever Syndromes, Hereditary, Lipid Metabolism, Inborn Errors
Interventions: Not listed
Lead sponsor: Oregon Health and Science University; Other
Eligibility: Not listed
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2016
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Amputation, Hyperhidrosis
Interventions: glycopyrronium cloths, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Murray, Utah

Conditions: Acne Vulgaris
Interventions: Not listed
Lead sponsor: Sienna Labs; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 16
States / cities: Scottsdale, Arizona • Santa Monica, California • Coral Gables, Florida + 13 more

Conditions: Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, HAE
Interventions: ADX-324 Dose Level 1, ADX-324 Dose Level 2; Drug
Lead sponsor: ADARx Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 15
States / cities: Litchfield Park, Arizona • Little Rock, Arkansas • San Diego, California + 12 more

Conditions: Methicillin Resistant Staphylococcus Aureus Skin Infections
Interventions: mupirocin and chlorhexidine, household cleaning and disinfection, mupirocin, chlorhexidine, & household cleaning/disinfection; Drug · Behavioral
Lead sponsor: loren g miller; Other
Eligibility: 1 Month and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 6
States / cities: Anaheim, California • Bellflower, California • Harbor City, California + 3 more

Conditions: Breast Cancer
Interventions: SIS TALK Back Intervention; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Richmond, Virginia

Conditions: Malignant Neoplasm of Breast TNM Staging Distant Metastasis (M), Untreated Bone Metastases
Interventions: NaF PET/MRI, NaF PET/CT, FDG PET/CT; Device
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Atopic Dermatitis
Interventions: Lebrikizumab, Placebo, TCS Cream; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 16
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 13 more

Conditions: Dystrophic Epidermolysis Bullosa
Interventions: PTW-002 10 mg/g gel, Placebo; Drug
Lead sponsor: Phoenicis Therapeutics; Industry
Eligibility: 4 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Stanford, California • Worcester, Massachusetts • Cincinnati, Ohio

Conditions: Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer, Thymus Cancer, Colon Cancer, Rectal Cancer, Gastrointestinal Stromal Tumors, Anal Cancer, Bile Duct Cancer, Duodenal Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Small Intestine Cancer, Peritoneal Surface Malignancies, Familial Adenomatous Polyposis, Lynch Syndrome, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer, Ureter Cancer, Urethral Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip Cancer, Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Paranasal Sinus Cancer, Nasal Cavity Cancer, Salivary Gland Cancer, Skin Cancer, Central Nervous System Tumor, Central Nervous System Cancer, Mesothelioma, Breast Cancer, Leukemia, Melanoma, Sarcoma, Unknown Primary Tumor, Multiple Myeloma, Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Neuroendocrine Tumors, Plasma Cell Dyscrasia, Healthy Control
Interventions: Not listed
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 110 Years
Enrollment: 999,999 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2099
U.S. locations: 42
States / cities: Greenwood Village, Colorado • Manchester, Connecticut • Daytona Beach, Florida + 34 more

Conditions: Breast Cancer
Interventions: Breath test; Diagnostic Test
Lead sponsor: SpotitEarly; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,204 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Totowa, New Jersey • Philadelphia, Pennsylvania

Conditions: Cold Sores
Interventions: Herpecin L; Other
Lead sponsor: Focus Consumer Healthcare; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Breast Cancer
Interventions: Aromatase inhibitors or tamoxifen; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Female only
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Skin Carcinoma, Skin Melanoma
Interventions: Written Educational Brochure, Online educational video; Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Healthy, no Evidence of Disease, Skin Cancer
Interventions: cholecalciferol; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 40 Years and older
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Melanoma
Interventions: DC Vaccine, Montanide Vaccine, Poly-ICLC; Biological
Lead sponsor: Nina Bhardwaj; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 2
States / cities: New York, New York

Conditions: Solid Tumor, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung
Interventions: ATI-1123 (active drug = docetaxel); Drug
Lead sponsor: Azaya Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Dallas, Texas • San Antonio, Texas

Conditions: Chronic Graft vs. Host Disease, GVHD, cGVHD, Graft Versus Host Disease in Skin
Interventions: Axatilimab; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer
Interventions: AMXT 1501 Dicaprate, DFMO, Fulvestrant, Capivasertib, Pembrolizumab; Drug
Lead sponsor: Aminex Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 20
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 15 more

Conditions: Melanoma
Interventions: PF-06688992; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

Dietary Cholesterol and Defects in Cholesterol Synthesis in Mevalonate Kinase Deficiency

Qbrexza Cloths for Hyperhidrosis of Amputation Sites

Long-term Follow-up Study of Subjects Who Completed Clinical Studies 755.1100_FA, 810.1100_FA, or 1064.1100_FA

Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)

A Randomized Clinical Trial to Prevent Recurrent CA-MRSA Infection

Improving Communication and Adherence in Black Breast Cancer Survivors (Sisters Informing Sisters)

NaF PET/MRI Evaluation for Bone Metastases in Breast Cancer

A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis

Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa Due to Mutation(s) in Exon 73 of the COL7A1 Gene

Integrated Cancer Repository for Cancer Research

Identification of Breast Cancer in Breath Samples Using Trained Detection Dogs

An Investigation Into the Efficacy of Herpecin L at Reducing the Frequency and Severity of Cold Sores

Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer

Improving Sun-Protective Behaviors and Skin Self-Examinations Among African Americans

Vitamin D Levels in the Skin of Healthy Subjects After Oral Supplementation

A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence

Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies

Effects of Axatilimab on Skin in Chronic Graft-versus-Host Disease

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma